Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICVB-1042 in advanced solid tumors
NCT05904236Phase 1Terminated
- Sponsor
- IconOVir Bio
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Adenoviral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICVB-1042 in solid tumor (advanced stage), sponsored by IconOVir Bio. Primary endpoint: Safety of intravenous ICVB-1042 at 12 weeks. Started Jun 2023; status: terminated.
02
Drugs
ICVB-1042
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05904236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904236.